LV11730B - Metode iekapsulētu šūnu implantēšanai saimniekam - Google Patents
Metode iekapsulētu šūnu implantēšanai saimniekam Download PDFInfo
- Publication number
- LV11730B LV11730B LVP-96-434A LV960434A LV11730B LV 11730 B LV11730 B LV 11730B LV 960434 A LV960434 A LV 960434A LV 11730 B LV11730 B LV 11730B
- Authority
- LV
- Latvia
- Prior art keywords
- cells
- celis
- implantation
- encapsulated
- capsule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0613—Cells from endocrine organs
- C12N5/0614—Adrenal gland
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Claims (10)
- LV 11730 IZGUDROJUMA FORMULA 1. Metode iekapsulētu šūnu iegūšanai implantēšanai saimniekam implantācijas vietā, kas ietver stadijas: 5 (a) šūnu iekapsulēšanu bioloģiski saderīgā kapsulā un (b) šūnu izturēšanu pie vismaz viena ierobežojoša nosacījuma, kas tuvu atbilst nosacījumam implantācijas vietā un kurš nostiprina izmērījamu izmaiņu vismaz vienā šūnu īpašībā kā atbildi uz ierobežojošo nosacījumu.
- 2. Metode saskaņā ar 1. punktu, kur iekapsulētās šūnas tiek izturētas pie ierobežojoša nosacījuma vai nosacījumiem in vitro.
- 3. Metode saskaņā ar 1. punktu, kur iekapsulētās šūnas tiek izturētas pie ierobežojoša nosacījuma vai nosacījumiem in vivo, implantējot tās 15 recipientam implantācijas vietā.
- 4. Metode saskaņā ar 1. punktu, kur šūnas ir ksenogēnas saimniekam un kapsula ir imunoizolējoša.
- 5. Metode saskaņā ar 1. punktu, kur vismaz viens ierobežojošais nosacījums ir glikozes koncentrācija, kas svārstās robežās no aptuveni 40 mg decilitrā līdz aptuveni 70 mg decilitrā.
- 6. Metode saskaņā ar 1. punktu, kur vismaz viens ierobežojošais 25 nosacījums ir skābekļa koncentrācija, kas svārstās robežās no aptuveni 40 mmHg līdz aptuveni 65 mmHg.
- 7. Metode saskaņā ar 1. punktu, kur vismaz viens ierobežojošais nosacījums ir dopamīna koncentrācija, kas ir zemāka par fizioloģisko 30 dopamīna koncentrāciju cerebrospinālajā šķidrumā vai smadzeņu parenhīmā.
- 8. Metode saskaņā ar 3. punktu, kur šūnas ir izvēlētas no grupas, kurā ietilpst virsnieru hromafīnās šūnas, kāmja mazuļa nieru šūnas un PC12 šūnas. 35 2 II
- 9. Metode saskaņā ar 8. punktu, kur šūnas ir PC12 šūnas un tās tiek implantētas recipientam uz 6 mēnešiem vai ilgāku laiku. 10. 5 Metode saskaņā ar 8. punktu, kur šūnas ir virsnieru hromafīnās šūnas un tās tiek implantētas recipientam uz 4 mēnešiem vai ilgāku laiku. 11. Metode saskaņā ar 8. punktu, kur šūnas ir PC12 šūnas un tās tiek implantētas recipientam uz 3 nedēļām vai ilgāku laiku. 10 12. Metode saskaņā ar 1. punktu, kur šūnas producē bioloģiski aktīvu molekulu, kas izvēlēta no grupas, kurā ietilpst neiromediatori, analgētiķi un augšanas faktori. 13. 15 Metode saskaņā ar 12. punktu, kur bioloģiski aktīvā molekula ir kateholamīns. 14. Metode saskaņā ar 3. punktu, kur kapsula tiek implantēta recipientam implantācijas vietā, kas var būt cerebrospinālais šķidrums vai smadzeņu parenhīma. 20 15. Metode saskaņā ar 1. punktu, kur saimnieks ir cilvēks. 16. Metode iekapsulētu šūnu iegūšanai implantēšanai implantācijas vietā ksenogēnam saimniekam, kas ietver stadijas: 25 (a) šūnu kultivēšanu pie diviem vai vairākiem ierobežojošiem 30 nosacījumiem, (b) šūnu iekapsulēšanu bioloģiski saderīgā kapsulā un tālāku iekapsulēto šūnu izturēšanu pie vismaz viena ierobežojoša nosacījuma, kas tuvu atbilst nosacījumam implantācijas vietā un kurš nostiprina izmērījamu izmaiņu vismaz vienā šūnu īpašībā kā atbildi uz ierobežojošo nosacījumu. 17. Šūnas implantēšanai izvēlētā implantācijas vietā saimniekam, kuras 35 iegūtas ar metodi, kas ietver stadijas: (a) šūnu iekapsulēšanu bioloģiski saderīgā kapsulā un (b) iekapsulēto šūnu izturēšanu pie vismaz viena ierobežojoša nosacījuma, kas tuvu atbilst nosacījumam izvēlētajā implantācijas vietā 3 III LV 11730 un kurš nodrošina izmērījamu izmaiņu vismaz viena šūnu īpašībā kā atbildi uz ierobežojošo nosacījumu. 18. 5 Šūnas saskaņā ar 17. punktu, kas iegūtas, izturot iekapsulētās šūnas pie ierobežojoša nosacījuma vai nosacījumiem in vitro. 19. Šūnas saskaņā ar 17. punktu, kas iegūtas, izturot iekapsulētās šūnas pie ierobežojoša nosacījuma vai nosacījumiem in vivo, implantējot tās recipientam implantācijas vietā. 10 20. Šūnas saskaņā ar 19. punktu, kur iekapsulētās šūnas tiek implantētas implantācijas vietā primāta recipientam vismaz uz 6 mēnešiem, lai nostiprinātu šūnu īpašību kā atbildi uz implantācijas vietā sastaptu ierobežojošo nosacījumu vai nosacījumiem, pie tam šūnas ir ksenogēnas 15 recipientam. 21. Šūnas saskaņā ar 19. punktu, kur šūnas ir izvēlētas no grupas, kurā ietilpst virsnieru hromafīnās šūnas, kas nav primāta šūnas, kāmja mazuļa nieru šūnas un PC12 šūnas. 20 22. Šūnas saskaņā ar 19. punktu, kur šūnas ir virsnieru hromafīnās šūnas, kas nav primāta šūnas. 23. 25 24. Šūnas saskaņā ar 19. punktu, kur šūnas ir PC12 šūnas. Šūnas saskaņā ar 22. vai 23. punktu, kur vēlamā šūnu īpašība ir izmainīts šūnu producētā kateholamīna daudzums. 25. Šūnas saskaņā ar 24. punktu, kur vēlamā šūnu īpašība ir palielināts šūnu 30 producētā kateholamīna daudzums. 26. Šūnas saskaņā ar 19. punktu, kur implantācijas vieta recipientam ir cerebrospinālais šķidrums vai smadzeņu parenhīma. 35 27. Šūnas saskaņā ar 17. punktu, kur saimnieks ir cilvēks. II 4
- 28. Bioloģiski saderīga kapsula, kas satur šūnas, kuras sagatavotas implantēšanai izvēlētā implantācijas vietā saimniekam, pie tam šūnas iegūtas ar metodi, kas ietver stadijas: (a) šūnu iekapsulēšanu bioloģiski saderīgā kapsulā un 5 (b) iekapsulēto šūnu izturēšanu pie vismaz viena ierobežojoša nosacījuma, kas tuvu atbilst nosacījumam implantācijas vietā un kurš nostiprina izmērījamu izmaiņu vismaz vienā šūnu īpašībā kā atbildi uz ierobežojošo nosacījumu.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/228,403 US5550050A (en) | 1994-04-15 | 1994-04-15 | Method for implanting encapsulated cells in a host |
PCT/US1995/004564 WO1995028166A2 (en) | 1994-04-15 | 1995-04-13 | Method for implanting encapsulated cells in a host |
Publications (2)
Publication Number | Publication Date |
---|---|
LV11730A LV11730A (lv) | 1997-04-20 |
LV11730B true LV11730B (lv) | 1998-02-20 |
Family
ID=22857036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-96-434A LV11730B (lv) | 1994-04-15 | 1996-11-15 | Metode iekapsulētu šūnu implantēšanai saimniekam |
Country Status (19)
Country | Link |
---|---|
US (1) | US5550050A (lv) |
EP (2) | EP0756487A1 (lv) |
JP (2) | JPH10501792A (lv) |
CN (1) | CN1146155A (lv) |
AU (1) | AU697600B2 (lv) |
BR (1) | BR9507391A (lv) |
CA (1) | CA2187335A1 (lv) |
CZ (1) | CZ300496A3 (lv) |
EE (1) | EE9600147A (lv) |
FI (1) | FI964124A (lv) |
HU (1) | HUT75661A (lv) |
IL (1) | IL113390A0 (lv) |
IS (1) | IS4368A (lv) |
LV (1) | LV11730B (lv) |
NO (1) | NO964358L (lv) |
PL (1) | PL316845A1 (lv) |
SK (1) | SK131696A3 (lv) |
WO (1) | WO1995028166A2 (lv) |
ZA (1) | ZA953126B (lv) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2121129A1 (en) * | 1991-10-29 | 1993-05-13 | Patrick Soon-Shiong | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
US5908623A (en) * | 1993-08-12 | 1999-06-01 | Cytotherapeutics, Inc. | Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
US5840576A (en) | 1994-07-20 | 1998-11-24 | Cytotherapeutics, Inc. | Methods and compositions of growth control for cells encapsulated within bioartificial organs |
US5935849A (en) * | 1994-07-20 | 1999-08-10 | Cytotherapeutics, Inc. | Methods and compositions of growth control for cells encapsulated within bioartificial organs |
US5620013A (en) * | 1994-10-21 | 1997-04-15 | American Cyanamid Company | Method for destroying residual lens epithelial cells |
US5762925A (en) * | 1994-11-03 | 1998-06-09 | Sagen; Jacqueline | Preventing opiate tolerance by cellular implantation |
US6495364B2 (en) | 1995-05-23 | 2002-12-17 | Neurotech, S.A. | Mx-1 conditionally immortalized cells |
US5855613A (en) | 1995-10-13 | 1999-01-05 | Islet Sheet Medical, Inc. | Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change |
PT888385E (pt) | 1996-03-14 | 2004-01-30 | Genentech Inc | Utilizacoes de gdnf e de receptores de gdnf |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
US6027721A (en) * | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
US6150164A (en) * | 1996-09-30 | 2000-11-21 | The Regents Of The University Of Michigan | Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo |
US6074825A (en) * | 1997-07-31 | 2000-06-13 | Maine Medical Center | Stable encapsulated reference nucleic acid and method of making |
US6399058B1 (en) * | 1997-09-17 | 2002-06-04 | Alcon Manufacturing, Ltd. | Methods for treating ocular diseases |
WO1999013726A1 (en) * | 1997-09-19 | 1999-03-25 | University Of South Florida | Neuronal cells and an immunosuppressant and anti-inflammatory factor |
US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
US6303136B1 (en) * | 1998-04-13 | 2001-10-16 | Neurotech S.A. | Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane |
US6184035B1 (en) | 1998-11-18 | 2001-02-06 | California Institute Of Technology | Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells |
US6610540B1 (en) * | 1998-11-18 | 2003-08-26 | California Institute Of Technology | Low oxygen culturing of central nervous system progenitor cells |
US6713293B1 (en) | 1999-02-08 | 2004-03-30 | Friedrich Grummt | Encapsulated cells containing an amplified expression vector as a drug delivery device |
US6395299B1 (en) | 1999-02-12 | 2002-05-28 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
US6303355B1 (en) | 1999-03-22 | 2001-10-16 | Duke University | Method of culturing, cryopreserving and encapsulating pancreatic islet cells |
US20070071734A1 (en) * | 1999-04-06 | 2007-03-29 | Weng Tao | ARPE-19 as platform cell line for encapsulated cell-based delivery |
US6361771B1 (en) | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
WO2000066188A2 (en) * | 1999-04-30 | 2000-11-09 | Diatranz Limited | Xenotransplant for cns therapy |
US20090047325A1 (en) * | 1999-04-30 | 2009-02-19 | Neurotrophincell Pty. Limited | Xenotransplant for cns therapy |
US20040213768A1 (en) * | 1999-04-30 | 2004-10-28 | Elliott Robert Bartlett | Preparation for biotransplantation and xenotransplantion and uses thereof |
US20050265977A1 (en) * | 1999-04-30 | 2005-12-01 | Elliott Robert B | Xenotransplant for CNS therapy |
US7122177B2 (en) * | 2000-01-20 | 2006-10-17 | Diabcell Pty Ltd. | Preparation and xenotransplantation of porcine islets |
AU2001233168A1 (en) * | 2000-01-31 | 2001-08-07 | Children's Medical Center Corporation | Neural regeneration conduit |
US6719970B1 (en) * | 2000-07-10 | 2004-04-13 | Alkermes Controlled Therapeutics, Inc. | Method of generating cartilage |
US20040014212A1 (en) * | 2000-10-17 | 2004-01-22 | Elliott Robert Bartlett | Preparation and xenotransplantation or porcine islets |
US6538010B1 (en) * | 2000-11-08 | 2003-03-25 | Research Triangle Institute | Compounds and methods for promoting smoking cessation |
ATE443131T1 (de) * | 2001-07-10 | 2009-10-15 | Biogen Idec Inc | Hemmung des apoptoseprozesses und verbesserung der zelleistung |
EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
US7332330B2 (en) | 2001-09-11 | 2008-02-19 | Renamed Biologics, Inc. | Device for maintaining vascularization near an implant |
US20050042746A1 (en) * | 2001-09-28 | 2005-02-24 | Olga Garkavenko | Growing xenotransplant material in culture |
US20030068308A1 (en) * | 2001-10-09 | 2003-04-10 | Jacek Rozga | Intrasplenic encapsulated cell therapy |
NZ515310A (en) * | 2001-11-07 | 2004-08-27 | Diabcell Pty Ltd | Methods of treatment and delivery modes |
US7442546B2 (en) * | 2002-03-15 | 2008-10-28 | The Regents Of The University Of Michigan | Method of modulating inflammatory response |
US20030228261A1 (en) * | 2002-06-05 | 2003-12-11 | Aladar Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
EP1369491A1 (en) * | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
AU2002952993A0 (en) | 2002-11-29 | 2002-12-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Therapeutic and diagnostic agents |
AU2003901325A0 (en) * | 2003-03-21 | 2003-04-03 | Stephen Locarnini | Therapeutic, prophylactic and diagnostic agents |
AU2004224825A1 (en) * | 2003-03-26 | 2004-10-07 | Crc For Asthma Limited | Therapeutic and prophylactic compositions and uses therefor |
CN100475846C (zh) | 2003-06-10 | 2009-04-08 | Ns基因公司 | 增加的神经胚素分泌 |
MXPA05013879A (es) * | 2003-06-18 | 2006-06-27 | Genelux Corp | Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos. |
EP1636346A4 (en) * | 2003-06-24 | 2007-03-28 | Diabcell Pty Ltd | FROM PIG CULTIVATED PIG ISLE CELLS FOR XENOTRANSPLANTATION |
EP1667516A4 (en) | 2003-08-29 | 2009-11-11 | Inst Medical W & E Hall | METHOD FOR SELECTION OF ANIMAL MODELS FROM ANIMALS MUTAGENICALLY SUBJECTED AND THE USE OF MYB TRANSCRIPTION FACTORS FOR SCREENING |
EP1677676A4 (en) * | 2003-09-05 | 2011-02-23 | Univ Ohio State Res Found | NANOTEILIC PROBE FOR IN VIVO MONITORING OF TISSUE OXYGENATION |
US8066973B2 (en) * | 2003-09-05 | 2011-11-29 | The Ohio State University Research Foundation | Nanoparticulate probe for in vivo monitoring of tissue oxygenation |
AU2004283053A1 (en) | 2003-10-20 | 2005-05-06 | Nsgene A/S | In vivo gene therapy of Parkinson's Disease |
EP1696822B1 (en) * | 2003-11-13 | 2010-03-17 | PSivida US Inc. | Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin |
DE602005010047D1 (de) * | 2004-01-19 | 2008-11-13 | Nsgene As | Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen |
US20070281986A1 (en) * | 2004-02-03 | 2007-12-06 | Collier Gregory R | Methods and Compositions for Modulating Satiety |
NZ550542A (en) | 2004-03-30 | 2009-03-31 | Nsgene As | Therapeutic use of a growth factor, NsG33 |
JP4980211B2 (ja) | 2004-05-12 | 2012-07-18 | ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | 細胞単離方法 |
WO2006013462A2 (en) * | 2004-07-30 | 2006-02-09 | Nsgene A/S | Growth factors nsg28, nsg30, and nsg32 |
AU2006228873B2 (en) * | 2005-04-01 | 2011-08-18 | Nsgene A/S | A human immortalised neural precursor cell line |
US9364427B2 (en) * | 2005-05-17 | 2016-06-14 | Nsgene A/S | Implantable therapy system for treating a living being with an active factor |
NZ540597A (en) * | 2005-06-08 | 2007-02-23 | Neurotrophincell Pty Ltd | A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells |
EP2407484B1 (en) | 2005-06-24 | 2016-06-22 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same |
WO2007048413A1 (en) * | 2005-10-28 | 2007-05-03 | Nsgene A/S | IMPLANTABLE BIOCOMPATIBLE IMMtTNOISOLATORY VEHICLE FOR DELIVERY OF GDNF |
DE102005061801A1 (de) * | 2005-12-23 | 2007-06-28 | BSH Bosch und Siemens Hausgeräte GmbH | Einschubdosiersystem für Haushaltsgeräte |
US9265814B2 (en) * | 2005-12-30 | 2016-02-23 | Neurotech Usa, Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
AU2007275764B2 (en) | 2006-07-18 | 2013-11-14 | University Of Utah Research Foundation | Methods for treating pain and screening analgesic compounds |
KR101760139B1 (ko) | 2007-06-29 | 2017-07-31 | 클라렌슈 피티와이 리미티드 | 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물 |
CN101868241A (zh) | 2007-09-28 | 2010-10-20 | 英特瑞克斯顿股份有限公司 | 表达生物治疗分子的治疗基因开关构建物和生物反应器以及它们的应用 |
US20090090214A1 (en) * | 2007-10-04 | 2009-04-09 | Chung Yuan Christian University | Method for forming nano-scale metal particles |
US20090196854A1 (en) * | 2008-02-04 | 2009-08-06 | Kytos Biosystems S.A. | Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery |
US20100021437A1 (en) * | 2008-04-07 | 2010-01-28 | The McLean Hospital Corporation Whitehead Institute for Biomedical Research | Neural stem cells derived from induced pluripotent stem cells |
US8741340B2 (en) | 2009-01-23 | 2014-06-03 | Nsgene A/S | Cell lines and their use in encapsulated cell biodelivery |
EP2389191A2 (en) | 2009-01-23 | 2011-11-30 | NsGene A/S | Expression of neuropeptides in mammalian cells |
CA2759244A1 (en) * | 2009-04-23 | 2010-10-28 | Neurotech Usa, Inc. | Cell lines that produce prostaglandin f2 alpha (pgf2a) and uses thereof |
FR2948125B1 (fr) | 2009-07-17 | 2011-08-26 | Zoran Dermanovic | Procedes d'etablissement de symbioses |
EP2482828B1 (en) | 2009-10-02 | 2014-12-17 | Baxter International Inc | Hematopoietic stem cells for use in the treatment of a kidney injury |
JP2013507373A (ja) * | 2009-10-08 | 2013-03-04 | ニューロテック ユーエスエー, インコーポレイテッド | 被包された細胞ベースの送達系におけるpedfの使用 |
CA2813013C (en) | 2010-10-01 | 2019-10-22 | Nsgene A/S | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
MX2013006216A (es) | 2010-12-02 | 2013-10-17 | Neurotech Usa Inc | Lineas celulares que secretan andamios de anticuerpos anti-angionicos y receptores solubles y sus usos. |
JP2012215543A (ja) * | 2011-03-31 | 2012-11-08 | Sony Corp | 個体情報の判定方法、個体情報判定装置、電子機器及び個体情報判定プログラム |
CN104105501B (zh) | 2011-09-05 | 2017-10-20 | 霍巴治疗公司 | 异常性疼痛、痛觉过敏、自发性疼痛、和幻痛的治疗 |
US20130216495A1 (en) | 2012-02-21 | 2013-08-22 | Baxter Healthcare Sa | Pharmaceutical composition comprising cd34+ cells |
JP2015519370A (ja) | 2012-05-30 | 2015-07-09 | ニューロテック ユーエスエー, インコーポレイテッド | 低温保存される植込み型細胞培養デバイスおよびその使用 |
JP6234485B2 (ja) | 2013-03-07 | 2017-11-22 | ヴィアサイト インコーポレイテッド | 3次元大収容力細胞封入デバイスアセンブリー |
JP6681826B2 (ja) | 2013-05-31 | 2020-04-15 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | コノトキシンペプチド、医薬組成物およびそれらの使用 |
AU2014318846A1 (en) | 2013-09-11 | 2016-03-10 | Neurotech Usa, Inc. | Encapsulated cell therapy cartridge |
CA2986769A1 (en) | 2015-05-27 | 2016-12-01 | Neurotech Usa, Inc. | Use of encapsulated cell therapy for treatment of ophthalmic disorders |
CN108884135B (zh) | 2015-10-27 | 2024-03-26 | 昆士兰大学 | 治疗方法以及可用于其中的药剂 |
WO2022011081A1 (en) | 2020-07-09 | 2022-01-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cell lines that produce human retinoschisin proteins and uses thereof |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4409331A (en) * | 1979-03-28 | 1983-10-11 | Damon Corporation | Preparation of substances with encapsulated cells |
US4298002A (en) * | 1979-09-10 | 1981-11-03 | National Patent Development Corporation | Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation |
US4353888A (en) * | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
NO163060C (no) * | 1981-03-13 | 1990-03-28 | Damon Biotech Inc | Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer. |
JPS5876086A (ja) * | 1981-10-28 | 1983-05-09 | Ajinomoto Co Inc | 浮遊性動物細胞の培養法 |
US4479796A (en) * | 1982-11-15 | 1984-10-30 | Medtronic, Inc. | Self-regenerating drug administration device |
EP0127989A3 (en) * | 1983-06-01 | 1986-03-26 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
US4689293A (en) * | 1983-06-06 | 1987-08-25 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
US4806355A (en) * | 1983-06-06 | 1989-02-21 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
JPS60141286A (ja) * | 1983-12-28 | 1985-07-26 | Ajinomoto Co Inc | 動物細胞の培養方法および装置 |
US4749620A (en) * | 1984-02-15 | 1988-06-07 | Massachusetts Institute Of Technology | Encapsulated active material system |
CA1215922A (en) * | 1984-05-25 | 1986-12-30 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
GB8500121D0 (en) * | 1985-01-03 | 1985-02-13 | Connaught Lab | Microencapsulation of living cells |
US4868121A (en) | 1985-02-07 | 1989-09-19 | Mcdonnell Douglas Corporation | Islet isolation process |
US4902295A (en) * | 1985-08-26 | 1990-02-20 | Hana Biologics, Inc. | Transplantable artificial tissue |
US4753635A (en) | 1986-05-23 | 1988-06-28 | Jacqueline Sagen | Inducing analgesia by implantation of cells releasing neuroactive substances |
US5026365A (en) * | 1987-04-29 | 1991-06-25 | The University Of Massachusetts | Method and apparatus for therapeutically treating immunological disorders and disease states |
DE3724798A1 (de) * | 1987-07-27 | 1989-02-09 | Mengele & Soehne Masch Karl | Erntevorsatz an feldhaeckslern |
US4942129A (en) * | 1987-07-28 | 1990-07-17 | Queen's University At Kingston | Multiple membrane microencapsulation |
US5106627A (en) * | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5182111A (en) * | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
KR0132666B1 (en) * | 1989-03-14 | 1998-04-14 | Hitachi Kk | Method for controlling cultivation conditions for animal cells |
US5002661A (en) * | 1989-08-25 | 1991-03-26 | W. R. Grace & Co.-Conn. | Artificial pancreatic perfusion device |
WO1991009119A1 (en) * | 1989-12-13 | 1991-06-27 | Trancel Corporation | Improved alginate microcapsules, methods of making and using same |
WO1991010470A1 (en) * | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
US5084350A (en) * | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
AU8649391A (en) | 1990-08-15 | 1992-03-17 | University Of Miami | Autotransplantation of schwann cells to promote nervous system repair |
DK0585368T3 (da) * | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
ES2100354T3 (es) | 1991-06-28 | 1997-06-16 | Univ Brown Res Found | Sistema de implante nervioso. |
CA2134088A1 (en) * | 1992-04-24 | 1993-11-11 | Robert S. Ward | Method of culturing viable cells and method of regulating the level of a compound in a body fluid |
WO1994003154A1 (en) | 1992-07-29 | 1994-02-17 | Washington University | Use of pouch for implantation of living cells |
WO1995001203A2 (en) | 1993-06-23 | 1995-01-12 | Cytotherapeutics, Inc. | Implantable membrane encapsulation apparatus |
EP0802800B1 (en) | 1993-08-12 | 2002-06-12 | Neurotech S.A. | Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
-
1994
- 1994-04-15 US US08/228,403 patent/US5550050A/en not_active Expired - Lifetime
-
1995
- 1995-04-13 HU HU9602850A patent/HUT75661A/hu unknown
- 1995-04-13 WO PCT/US1995/004564 patent/WO1995028166A2/en not_active Application Discontinuation
- 1995-04-13 CZ CZ963004A patent/CZ300496A3/cs unknown
- 1995-04-13 EP EP95916970A patent/EP0756487A1/en not_active Ceased
- 1995-04-13 EP EP05023484A patent/EP1632238A1/en not_active Withdrawn
- 1995-04-13 CN CN95192579A patent/CN1146155A/zh active Pending
- 1995-04-13 AU AU23829/95A patent/AU697600B2/en not_active Ceased
- 1995-04-13 EE EE9600147A patent/EE9600147A/xx unknown
- 1995-04-13 SK SK1316-96A patent/SK131696A3/sk unknown
- 1995-04-13 BR BR9507391A patent/BR9507391A/pt not_active Application Discontinuation
- 1995-04-13 PL PL95316845A patent/PL316845A1/xx unknown
- 1995-04-13 JP JP7527082A patent/JPH10501792A/ja active Pending
- 1995-04-13 CA CA002187335A patent/CA2187335A1/en not_active Abandoned
- 1995-04-14 IL IL11339095A patent/IL113390A0/xx unknown
- 1995-04-18 ZA ZA953126A patent/ZA953126B/xx unknown
-
1996
- 1996-10-01 IS IS4368A patent/IS4368A/is unknown
- 1996-10-14 NO NO964358A patent/NO964358L/no not_active Application Discontinuation
- 1996-10-14 FI FI964124A patent/FI964124A/fi unknown
- 1996-11-15 LV LVP-96-434A patent/LV11730B/lv unknown
-
2005
- 2005-03-16 JP JP2005076076A patent/JP2005239726A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NO964358D0 (no) | 1996-10-14 |
EP1632238A1 (en) | 2006-03-08 |
NO964358L (no) | 1996-12-13 |
AU2382995A (en) | 1995-11-10 |
BR9507391A (pt) | 1997-09-16 |
US5550050A (en) | 1996-08-27 |
ZA953126B (en) | 1996-01-04 |
IL113390A0 (en) | 1995-07-31 |
HU9602850D0 (en) | 1996-12-30 |
PL316845A1 (en) | 1997-02-17 |
EP0756487A1 (en) | 1997-02-05 |
JP2005239726A (ja) | 2005-09-08 |
FI964124A0 (fi) | 1996-10-14 |
AU697600B2 (en) | 1998-10-08 |
LV11730A (lv) | 1997-04-20 |
WO1995028166A2 (en) | 1995-10-26 |
HUT75661A (en) | 1997-05-28 |
IS4368A (is) | 1996-10-01 |
CZ300496A3 (en) | 1997-03-12 |
SK131696A3 (en) | 1997-06-04 |
JPH10501792A (ja) | 1998-02-17 |
FI964124A (fi) | 1996-10-14 |
CN1146155A (zh) | 1997-03-26 |
CA2187335A1 (en) | 1995-10-26 |
MX9604832A (es) | 1998-06-28 |
EE9600147A (et) | 1997-04-15 |
WO1995028166A3 (en) | 1995-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU697600B2 (en) | Method for implanting encapsulated cells in a host | |
EP0802800B1 (en) | Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules | |
US5908623A (en) | Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules | |
Emerich et al. | Implants of polymer‐encapsulated human NGF‐secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons | |
US5869077A (en) | Methods for treating diabetes by delivering insulin from biocompatible cell-containing devices | |
US5800829A (en) | Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core | |
Sagot et al. | Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse | |
RU2234338C2 (ru) | Использование нейропроизводных эмбриональных клеточных линий для трансплантационной терапии | |
Tseng et al. | Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy |